Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta
Georgia
30005
United States
Tel: 678-270-3631
Fax: 678-270-4033
Website: http://www.clearsidebio.com/
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Stock Symbol: CLSD
Stock Exchange: NASDAQ
129 articles with Clearside Biomedical, Inc.
-
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update
5/11/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
5/5/2022
Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting.
-
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022
4/29/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2022 financial results will be reported on Wednesday, May 11, 2022 after the close of the financial markets
-
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
3/28/2022
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the U.S. commercial launch of XIPERE®.
-
Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/10/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
-
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
3/3/2022
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Benjamin R. Yerxa, Ph.D., has been appointed to the Company's Board of Directors, effective March 2, 2022.
-
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022
3/1/2022
Clearside Biomedical, Inc. announced that it will participate in the following investor conferences in March 2022.
-
Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022
2/25/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 10, 2022 after the close of the financial markets.
-
Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference
2/14/2022
Clearside Biomedical, Inc. announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector® were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022.
-
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022
2/2/2022
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Clearside’s SCS injection platform featuring the SCS Microinjector® will be featured in multiple oral presentations at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event to be held February 11-12, 2022.
-
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
12/21/2021
Clearside Biomedical, Inc. announced today positive safety results from OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector®.
-
Clearside Biomedical Added to the Nasdaq Biotechnology Index
12/13/2021
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that the Company will be added to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 20, 2021.
-
Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings
11/16/2021
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that multiple presentations were given at the American Academy of Ophthalmology 2021, which took place November 12 - 15, 2021 in New Orleans, LA.
-
Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021
11/11/2021
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it will participate in the following investor events, which will each be held in a virtual meeting format.
-
Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update
11/10/2021
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2021.
-
Clearside Biomedical to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Wednesday, November 10, 2021
10/28/2021
Clearside Biomedical, Inc. announced today that its third quarter 2021 financial results will be reported on Wednesday, November 10, 2021 after the close of the financial markets.
-
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
10/25/2021
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid
-
Xipere was approved for suprachoroidal use for the macular edema treatment. Macular edema is associated with uveitis, it is a form of eye inflammation.
-
The U.S. FDA has a busy period at the end of October heading into the first week of November.
-
Clearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) Annual Meeting
10/13/2021
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that multiple presentations were given at the American Society of Retina Specialists Annual Meeting and at the OIS Retina Summit at ASRS, which took place October 7 - 12, 2021 in San Antonio, TX.